Drugs / EA5
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07632976 | May 2026 → Sep 2027 expected | antiphospholipid syndrome, thrombotic disease | Shanghai Lanyi Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07256301 | Jan 2024 → Aug 2026 overdue | paroxysmal nocturnal hemoglobinuria | Shanghai Lanyi Therapeutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07256288 | May 2023 → Aug 2024 | — | Shanghai Lanyi Therapeutics Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EA5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07256288 ↗ |
| Modality | Monoclonal antibody | “humanized monoclonal antibody EA5” NCT07256301 ↗ |
| Route | Intravenous | “EA5 was administered intravenously.” NCT07256288 ↗ |